Table 1 Baseline characteristics of systematic reviews and meta-analyses included.
No | First author, year | Country | End search | N (studies) | n (patients) | Female (%) | Mean age (years) | Patients | Intervention | Outcome | Measure | Follow up time | Conflict of interest |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pairwise meta-analysis | |||||||||||||
1 | Goodarzi, 2019 | Iran | 20 Nov 2018 | 6 | 315 | 50.5 | 40–65 | NAFLD | Turmeric/curcumin | AST, ALT | MD | 8, 12, 24 weeks | No COI |
2 | Mansour-Ghanaei, 2019 | Iran | Dec 2017 | 4 | 228 | NR | Curcumin: 42.1–66.7 Placebo: 40.4–64.4 | NAFLD/NASH | Turmeric/curcumin | AST, ALT | MD | 8, 12 weeks | No COI |
3 | Wei, 2019 | China | Mar 2018 | 4 | 229 | 48.0 | Curcumin: 42.09–52.70 Placebo: 40.38–56.67 | NAFLD/NASH | Turmeric/curcumin | AST, ALT, TC, LDL, HDL, TG, FBS, HbA1c, insulin, HOMA-IR, weight | MD | 8, 12, 24 weeks | No COI |
4 | Jalali,2020 | Iran | 1 Sep 2019 | 9 | 588 | 46.4 | Curcumin: 41.8–46.64 Placebo: 37.75–48.95 | NAFLD | Curcumin only | AST, ALT, LDL, HDL, TC, TG, FBS, HbA1c, insulin, HOMA-IR, weight, WC, BMI | MD | 8, 12 weeks | No COI |
5 | Khalili, 2022 | Iran | April 2021 | 14 | 714 | NR | NR | NAFLD | Turmeric/curcumin | AST, ALT, TC, LDL, HDL, TG, FBS, BMI | SMD | 4, 8, 12 weeks | No COI |
Network meta-analysis | |||||||||||||
6 | Zhou, 2021 | China | 14 Aug 2020 | 35 (15 curcumin trials) | 5246 (934 in curcumin trials) | NR | Curcumin: 40.95–66.72 Placebo: 40.06–64.36 | NAFLD/NASH | Turmeric/curcumin, obeticholic acid, elafibranor, cenicriviroc, selonsertib, silymarin, resveratrol | Liver pathology improvement, AST, ALT, GGT, ALP, TC, TG, LDL, HDL | Exponential SMD | 8 weeks to 2 years (8–12 weeks for curcumin trials) | No COI |
